1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Diabetes Mellitus in 5 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluates the effect of intravitreal injection of a Rho-associated protein kinase (ROCK) inhibitor, fasudil, on diabetic macular edema (DME) with an unfavorable response." | 8.12 | Intravitreal Fasudil for Treatment of Diabetic Macular Edema with an Unfavorable Response. ( Machida, S; Muto, T, 2022) |
| "This study evaluates the effect of intravitreal injection of a Rho-associated protein kinase (ROCK) inhibitor, fasudil, on diabetic macular edema (DME) with an unfavorable response." | 4.12 | Intravitreal Fasudil for Treatment of Diabetic Macular Edema with an Unfavorable Response. ( Machida, S; Muto, T, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nagai, Y | 1 |
| Matoba, K | 1 |
| Yako, H | 1 |
| Ohashi, S | 1 |
| Sekiguchi, K | 1 |
| Mitsuyoshi, E | 1 |
| Sango, K | 1 |
| Kawanami, D | 1 |
| Utsunomiya, K | 1 |
| Nishimura, R | 1 |
| Muto, T | 1 |
| Machida, S | 1 |
| Ding, R | 1 |
| Hu, DY | 1 |
| Xia, K | 1 |
| Yang, XC | 1 |
| Gurpinar, T | 1 |
| Gok, S | 1 |
| Li, H | 1 |
| Peng, W | 1 |
| Jian, W | 1 |
| Li, Y | 1 |
| Li, Q | 1 |
| Li, W | 1 |
| Xu, Y | 1 |
1 trial available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Diabetes Mellitus
| Article | Year |
|---|---|
ROCK inhibitor fasudil attenuated high glucose-induced MCP-1 and VCAM-1 expression and monocyte-endothelial cell adhesion.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Anti-Inflammatory Agents; Blotting, Western; Ce | 2012 |
4 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Diabetes Mellitus
| Article | Year |
|---|---|
Rho-kinase inhibitor restores glomerular fatty acid metabolism in diabetic kidney disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Diabetes Mellitus; Diabetic Nephropathies; K | 2023 |
Intravitreal Fasudil for Treatment of Diabetic Macular Edema with an Unfavorable Response.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Diabetes Mellitus; Diabetic Retinopathy; Humans | 2022 |
Increased RhoA/ROK mRNA expression and function in diabetic vein grafts compared with nondiabetic vein grafts and diabetic arterial grafts.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Case-Control Studies; Coronary Artery By | 2010 |
Vasodilator effects of cromakalim and HA 1077 in diabetic rat aorta.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Aorta; Cromakalim; Diabetes Mellitus; In Vit | 2012 |